At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Placebo and Dupilumab for Atopic Dermatitis. Completed, enrolled 109 participants across 21 sites in 5 countries.
Detailed Summary
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCzechia, France, Germany, Hungary, Poland
CollaboratorsSanofi
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartApr 2012
Primary CompletionMar 2013
Study CompletionJun 2013
TodayJul 2026
First PostedMar 8, 2012
Enrollment StartApr 1, 2012
Primary CompletionMar 1, 2013
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.3 years ago
Interventions
Placebodrug
Subcutaneous injection altered between back of arms, abdomen and upper thighs.
Dupilumabdrug
Subcutaneous injection altered between back of arms, abdomen and upper thighs.